Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Completed 2Unknown 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 13Gastrointestinal 5Tumor-Agnostic 2Other solid neoplasm 1Other hematologic neoplasm 1CNS 1Breast 1

Conditions

Carcinoma, Hepatocellular 2Stomach Neoplasms 1Gastrointestinal Neoplasms 1Deafness, Autosomal Recessive 39 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 329Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 258lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
tepotinib × Gastrointestinal × Clear all
NCT04591431 2023-10-03

ROME

Fondazione per la Medicina Personalizzata

Phase 2 Unknown
400 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04515394 2022-12-22

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

EMD Serono

Phase 2 Terminated
3 enrolled 6 charts
Gastrointestinal

Deafness, Autosomal Recessive 39, Colorectal Neoplasms

NCT01988493 2022-08-24

Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
117 enrolled 30 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT02115373 2022-08-24

c-Met Second-Line Hepatocellular Carcinoma

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
66 enrolled 34 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT05439993 2022-07-05

Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma

Hallym University Medical Center

Phase 1/2 Recruiting
42 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡